Early data from a small phase Ib / II study [23] of ipilimumab
combined with T - VEC, which demonstrated that the combination offers much higher complete and overall response rates than have been seen with either
agent alone, appear to confirm that there are beneficial synergies between these two
therapeutic modalities.